-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NR7cZjiqfsvA67UK3mA9XUMsF+K0xWD8NVDPWQH3sFfpkEN5HmIuLjH8I2ju6Jgb
 MlEyVE2l9juavNAPbw/5/A==

<SEC-DOCUMENT>0000950123-09-047339.txt : 20090930
<SEC-HEADER>0000950123-09-047339.hdr.sgml : 20090930
<ACCEPTANCE-DATETIME>20090930154226
ACCESSION NUMBER:		0000950123-09-047339
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090929
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090930
DATE AS OF CHANGE:		20090930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		091095565

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c90623e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): September 29, 2009</B>

<P style="font-size: 24pt" align="center"><B>Lifevantage
Corporation<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>California</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>000-30489</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>90-0224471</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>11545 W. Bernardo Court,
Suite 301, San Diego, California<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>92127</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(858) 312-8000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;2.02 Results of Operations
and Financial Condition</B>

<P style="font-size: 10pt; text-indent: 3%" align="left">On September&nbsp;29,
2009, Lifevantage Corporation issued a press release entitled,
&#8220;Lifevantage Announces Fourth Quarter and Fiscal Year 2009
Financial and Operating Results&#8221;. The press release is attached as
Exhibit&nbsp;99.1 hereto, which is furnished under Item&nbsp;2.02 of this
report and shall not be deemed to be &#8220;filed&#8221; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the
&#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) or
the Exchange Act, regardless of any general incorporation language in such
filing.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;7.01 Regulation&nbsp;FD
Disclosure</B>

<P style="font-size: 10pt; text-indent: 3%" align="left">On September&nbsp;29,
2009, Lifevantage Corporation issued a press release entitled,
&#8220;Lifevantage Announces Fourth Quarter and Fiscal Year 2009
Financial and Operating Results&#8221;. The press release is attached as
Exhibit&nbsp;99.1 hereto, which is furnished under Item&nbsp;7.01 of this
report and shall not be deemed to be &#8220;filed&#8221; for purposes of
Section&nbsp;18 of the Exchange Act or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act or the Exchange Act, regardless of any general
incorporation language in such filing.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01 Exhibits</B>

<P style="font-size: 10pt; text-indent: 3%" align="left">99.1 Press release,
dated September&nbsp;29, 2009, entitled, &#8220;Lifevantage
Announces Fourth Quarter and Fiscal Year 2009 Financial and Operating
Results&#8221;.

<P style="font-size: 10pt; text-indent: 3%" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt" align="left">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.

<P style="font-size: 10pt" align="left">Date: September&nbsp;30, 2009


<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>

 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left" colspan="2">LIFEVANTAGE CORPORATION</TD>
</TR>

<TR><TD>&nbsp;</TD></TR>


<TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD align="left">By: </TD>
  <TD align="left" style="border-bottom: #000000 1px solid">/s/ Carrie E. Carlander</TD>
</TR>

<TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD align="left">Carrie E. Carlander<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>




<TABLE style="font-size: 10pt; text-align: center" cellspacing="0" cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>

<TR valign="bottom">
  <TD align="left" style="border-bottom: #000000 1px solid"><B>Exhibit<BR>Number</B></TD>
  <TD>&nbsp;</TD>
  <TD align="left" style="border-bottom: #000000 1px solid"><B>Description</B></TD>
</TR>




<TR valign="bottom">
  <TD align="left" valign="top">99.1</TD>
  <TD>&nbsp;</TD>
  <TD align="left">Press release, dated September&nbsp;29, 2009, entitled, &#8220;Lifevantage
Announces Fourth Quarter and Fiscal Year 2009 Financial and Operating Results&#8221;.</TD>
</TR>
</TABLE>


<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c90623exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c90623p9062301.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>LIFEVANTAGE ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2009 FINANCIAL AND<BR>
OPERATING RESULTS</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>San Diego</B>, <B>CA, September&nbsp;29, 2009</B>, <U>LifeVantage Corporation (OTCBB: LFVN),</U> a science-based, natural
products company dedicated to helping people reach their health and wellness goals through
science-based solutions for oxidative stress and the maker of both Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and TrueScience&#153;
Anti-Aging Cream, announced today fourth quarter and fiscal year 2009 financial and operating
results.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">The Company recorded net revenues of $4.1&nbsp;million and a net loss of ($9.1) million, or ($0.23) per
share, for its year ended June&nbsp;30, 2009. For its year ended June&nbsp;30, 2008, the Company recorded net
revenues of $3.2&nbsp;million and a net loss of ($2.1) million or ($0.09) per share.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">During its fourth quarter fiscal year 2009, the Company recorded net revenue of $1.6&nbsp;million, which
represents an increase of approximately 150% from the net revenue of $0.6&nbsp;million for the third
quarter fiscal year 2009 and a net loss of ($5.3) million or ($0.11) per share. During its fourth
quarter fiscal year 2008, the Company recorded net revenues of $0.8&nbsp;million and a net loss of
$(0.7) million, or $(0.03) per share.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#147;This past fiscal year has been a transitional one for LifeVantage,&#148; stated David W. Brown,
President &#038; CEO. &#147;We entered the multi-billion dollar network marketing industry, by far the
fastest growing sales channel for dietary supplements, and we believe, the best avenue for
marketing the Company&#146;s products. Furthermore, we announced a unique &#145;inside-out&#146; approach to
anti-aging with the launch of our second product, TrueScience Anti-Aging Cream. On the inside of
the body, Protandim, our flagship nutritional supplement, has been clinically proven to reduce the
rate of cellular aging. Offering a unique, effective skin care product to address the skin, or the
&#145;outside,&#146; was a logical extension of our Protandim product line. Continuing with our expansion, we
entered the international market with a pre-launch in Mexico, which ranks among the top five
countries in terms of network marketing, with a full launch anticipated later this year.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">&#147;The increase in yearly as well as fourth quarter revenue is directly attributable to our launch
into network marketing as well as the addition of a team of some of the most sought after and
highest producing independent distributors in the network marketing industry,&#148; added Brown.
&#147;Furthermore, we believe our executive team members, CFO Carrie Carlander and COO Kirby Zenger,
have proven to be tremendous assets to the Company. Carrie has an impressive background and track
record with dynamic public companies with proven abilities in corporate governance, strategic
planning, investor relations, and finance. Kirby brings varied and invaluable experience from the
network marketing industry as well as traditional business and has a proven track record in
building and growing network marketing sales organizations at an impressive rate. We believe the
team we now have in place can best continue to move the Company forward and significantly impact
the growth of our network marketing distribution model.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Carrie Carlander, CFO, added: &#147;Earlier this year, LifeVantage launched into the network marketing
sales channel and we look forward to continuing to realize the benefits of our new team and revenue
model. Most of the expenses related to the addition of the new team, marketing expenses necessary
to re-launch the Company and our second product, TrueScience Anti-Aging Cream, as well as
litigation expenses have now been recognized. We have also implemented reductions in overhead and
operating expenses and moving forward we are poised to execute our growth plans with a more
efficient corporate and operational structure.&#148;
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Key Corporate Developments</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>Third Patent for Protandim Issued</I></B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In September&nbsp;2009, the Company announced that it had been granted a third patent for Protandim,
"<I>Methods for Enhancing Antioxidant Enzyme Activity and Reducing C-Reactive Protein Levels,&#148; </I>which
was issued on August&nbsp;25, 2009. This patent claims the use of Protandim for increasing antioxidant
enzyme activity and further documents Protandim&#146;s effect on antioxidant enzymes in vivo, describing
anti-inflammatory effects such as the lowering of C-reactive protein. C-reactive protein is widely
considered by doctors and researchers as an indicator of the amount of inflammation present in the
body. Elevated basal levels of C-reactive protein are considered risk factors for diabetes,
hypertension, and cardiovascular disease.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c90623p9062301.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>Mexico Pre-Launch Announced</I></B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In August&nbsp;2009, the Company announced that it was entering the international market with a
pre-launch in Mexico, one of the top network marketing countries in the world, with independent
distributor applications and orders being accepted in anticipation of a launch later this year.
Network marketing companies have traditionally achieved outstanding results in Mexico and that,
coupled with the fact that LifeVantage has strong distributor relationships in the country, were
key factors in the expansion decision. As well, nutrition and wellness product sales are booming in
Mexico and the Company believes that Protandim and TrueScience are ideal for this market,
especially with the research and science that supports the Company&#146;s products.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>TrueScience Anti-Aging Cream Launched</I></B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In June&nbsp;2009, the Company launched its LifeVantage TrueScience Anti-Aging Cream, a
scientifically-based, groundbreaking and unique skin care product which includes natural and
effective ingredients, including those found in Protandim. This new, proprietary skin care formula
was developed in association with Kimberly Stone, M.D., a Denver-based board certified
dermatologist, and is formulated to protect the skin from a variety of factors that contribute to
aging and the symptoms of unhealthy skin.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>Peer-Reviewed Publications Surrounding Protandim</I></B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">During fiscal year 2009, several peer-reviewed preclinical studies involving our flagship product
Protandim, were published.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In April&nbsp;2009, the findings from a Louisiana State University peer-reviewed study were published in
the journal <I>PLoS ONE, </I>an international, peer-reviewed, open-access journal published by the Public
Library of Science. The abstract was entitled &#147;<I>Protandim, a Fundamentally New Antioxidant Approach
in Chemoprevention Using Mouse Two-Stage Skin Carcinogenesis as a Model</I>&#148;. A two-stage mouse skin
carcinogenesis study was performed to investigate whether Protandim could suppress tumor formation
by a dietary approach. The preclinical study concluded that overall, induction of antioxidant
enzymes by Protandim may serve as a practical and potent approach for cancer prevention.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">In February&nbsp;2009, the results of a preclinical study were published in the journal <I>Free Radical
Biology and Medicine</I>. The study was conducted by scientists at the University of Colorado Denver
and Ochsner Medical Center and demonstrated that all five of Protandim&#146;s active ingredients
contribute synergistically to the composition&#146;s activity, allowing it to work at low,
pharmacologically attainable doses of each. Even low doses of Protandim were shown to induce human
cells to increase their production of many antioxidant enzymes, and other anti-aging factors.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Furthermore, this study demonstrated that the synergistic impact of the active ingredients used in
the formulation of Protandim increases the cell&#146;s production of glutathione, a key antioxidant and
anti-aging factor, by more than 300&nbsp;percent, as well as increases the important antioxidant enzyme
heme oxygenase-1. Glutathione plays a key role in the immune system and when glutathione levels
drop, a person&#146;s ability to fight disease decreases. The study also demonstrated that Protandim
delivered antioxidant benefits to cells in ways that are not affected at all by conventional direct
antioxidants such as vitamins E and C.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Protandim is currently the subject of approximately 20 independent scientific studies at various
universities and research facilities. The nature and stages of the studies vary, as some are still
in planning stages, while other studies are currently in progress. Universities and institutions
conducting research include the University of Colorado; Colorado State University; Denver Health
Medical Center; Children&#146;s Hospital, Denver; the University of Florida; the University of Kentucky;
the University of Michigan; Louisiana State University; Ohio State University; Vanderbilt
University; Glamorgan University, Wales; Sahlgrenska University Hospital, Sweden; Harvard
University; and the Mexican Institute of Social Security, Mexico City. The various studies deal
with the alleviation of oxidative stress under the following conditions: altitude sickness,
non-alcoholic steatohepatitis, lung antioxidant status in withdrawing alcoholics, autonomic
physiology and aging, skin cancer, photoaging of the skin, osteoarthritis, HIV/AIDS-associated
lipodystrophy, pulmonary hypertension, periodontal disease, heart disease, coronary artery bypass
graft failure, asthma, Duchenne muscular dystrophy, metabolic syndrome, and optic neuropathy.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c90623p9062301.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About LifeVantage Corporation</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, nutraceutical company
dedicated to helping people reach their health and wellness goals. Founded in 2003 and based in San
Diego, CA, LifeVantage develops products, including Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, that deliver significant
health benefits to consumers. For more information, visit <U>www.LifeVantage.com</U>.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About Protandim</B><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP><BR>
Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is a clinically proven supplement that provides substantial benefits for
healthy aging. This patented indirect antioxidant therapy works in a very different way than
conventional foods such as red wine, oranges, blueberries or other popular antioxidant supplements.
Unlike those types of products that have proven to be largely ineffective in reducing oxidative
stress caused by free radicals, Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is an indirect antioxidant therapy, which
stimulates the body&#146;s production of its own powerful antioxidant enzymes. Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>
works at the cellular level, triggering cells to naturally increase production of protective
antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione synthase.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">A peer-reviewed human clinical study showed that after Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> was taken for 30
consecutive days, important biochemical markers of aging were decreased by an average of 40%. The
study also reported that these markers of aging were reduced in the subjects taking
Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> to the level of a typical 20&nbsp;year old. Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> is currently the
subject of approximately 20 scientific studies at various universities and research facilities. The
nature and stages of the studies vary, as some of the testing is at a preliminary stage, while
other studies using Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> are currently in progress. For more information about
Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, visit <u>www.LifeVantage.com</U>.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>About </B><B><I>LifeVantage TrueScience</I></B><B>&#153; Anti-Aging Cream</B><BR>
<I>LifeVantage TrueScience</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP> is scientifically-based and contains cutting-edge ingredients,
including those found in Protandim<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>. <I>LifeVantage TrueScience</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP> Anti-Aging
Cream gives skin a beautiful, even and smooth tone, diminishes the appearance of fine lines and
wrinkles, and provides a vibrant and glowing appearance. <I>LifeVantage TrueScience</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP> also
improves skin smoothness and pigmentation, while increasing skin moisture. For more information
about <I>LifeVantage TrueScience</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP>, visit <U>www.LifeVantage.com</U>.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>Forward Looking Statements</B><BR>
This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects, as well as words such as &#147;believe,&#148; &#147;hopes,&#148;
&#147;intends,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;projects,&#148; &#147;plans,&#148; &#147;anticipates&#148; and variations thereof,
identify forward-looking statements, but their absence does not mean that a statement is not
forward-looking. Such forward-looking statements are not guarantees of performance and the
Company&#146;s actual results could differ materially from those contained in such statements. These
forward-looking statements are based on the Company&#146;s current expectations and beliefs concerning
future events affecting the Company and involve known and unknown risks and uncertainties that may
cause the Company&#146;s actual results or outcomes to be materially different from those anticipated
and discussed herein. These risks and uncertainties include, among others, the potential failure or
unintended negative consequences of the implementation of our network marketing sales channel; our
ability to retain independent distributors or to attract new independent distributors on an ongoing
basis; the potential for third party and governmental actions involving our network marketing sales
channel; the potential for product liability claims against the Company; the risk that government
regulators and regulations could adversely affect our business; future laws or regulations may
hinder or prohibit the production or sale of our existing product and any future products;
unfavorable publicity could materially hurt our business; and the Company&#146;s ability to protect our
intellectual property rights and the value of our product. These and other risk factors are
discussed in greater detail in the Company&#146;s Annual Report on Form 10-K and Quarterly Report on
Form 10-Q under the caption &#147;Risk Factors&#148;, and in other documents filed by the Company from time
to time with the Securities and Exchange Commission. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this document. All forward-looking
statements are based on information currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these forward-looking statements to reflect
events or circumstances after the date of this document, except as required by law.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">*These statements have not been evaluated by the Food and Drug Administration. This product is not
intended to diagnose, treat, cure or prevent any disease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Investor Contact:</B><BR>
Ioana C. Hone<BR>
(858)&nbsp;312-8000 Ext. 4

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Media Contact:</B><BR>
For LifeVantage Corporation<BR>
Jan Strode, 619-890-4040<BR>
Jean Golden, 612-385-2324

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c90623p9062301.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>LIFEVANTAGE CORPORATION AND SUBSIDIARY<BR>
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">For the years ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">June 30, 2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">June 30, 2008</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sales, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,141,304</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,200,174</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cost of sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">852,804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">695,386</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Gross profit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,288,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,504,788</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Sales and marketing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,107,768</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,655,461</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,588,414</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,108,338</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">224,366</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">324,106</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">173,030</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">219,690</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,093,578</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,307,595</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Operating (loss)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7,805,078</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,802,807</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income and (expense):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,474</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45,315</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest (expense)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,330,030</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(296,947</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total other (expense)&nbsp;income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,309,556</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(251,632</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net (loss)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,114,634</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(2,054,439</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net (loss)&nbsp;per share, basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.23</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.09</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average shares outstanding, basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,360,592</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,710,096</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">The Notes included in the Form&nbsp;10-K for the year ended June&nbsp;30, 2009 are an integral part of these financial statements.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c90623p9062301.gif" alt="(LIFEVANTAGE LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>LIFEVANTAGE CORPORATION AND SUBSIDIARY<BR>
CONDENSED CONSOLIDATED BALANCE SHEETS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">June 30, 2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">June 30, 2008</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ASSETS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">608,795</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">196,883</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Restricted Cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">259,937</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Marketable securities, available for sale</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">520,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,100,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts receivable, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">648,116</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98,008</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Equity raise receivable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">119,750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">740,014</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">104,415</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72,049</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deposit with manufacturer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">277,979</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Prepaid expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72,738</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">124,049</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,985,832</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,973,383</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Long-term assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Marketable securities, available for sale</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">130,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">274,741</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63,559</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Intangible assets, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,175,281</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,270,163</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred debt offering costs, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83,023</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">193,484</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deposits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66,795</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48,447</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL ASSETS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,715,672</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,549,036</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">LIABILITIES AND STOCKHOLDERS&#146; (DEFICIT)&nbsp;EQUITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,029,290</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">139,803</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">822,024</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">338,268</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">510,765</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Escrow for equity offering</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">259,937</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Revolving line of credit and accrued interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">581,444</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">166,620</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Capital lease obligations, current portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41,490</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">846</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,734,185</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,156,302</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Long-term liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Deferred rent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,677</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Derivative warrant liability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,429,710</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Convertible debt, net of discount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">382,194</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">223,484</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,569,766</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,379,786</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitments and contingencies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; (deficit)&nbsp;equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Preferred stock &#151; par value $.001, 50,000,000 shares
authorized, no shares issued or outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock, &#151; par value $.001,
250,000,000 shares authorized
and 53,968,628 and 24,766,117 issued and
outstanding as of June&nbsp;30,
2009 and 2008, respectively</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53,969</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,766</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Additional paid-in capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,964,927</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,902,840</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated (deficit)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(23,872,990</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14,758,356</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total stockholders&#146; (deficit)&nbsp;equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6,854,094</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,169,250</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TOTAL LIABILITIES AND STOCKHOLDERS&#146; (DEFICIT)&nbsp;EQUITY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,715,672</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,549,036</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt">The Notes included in the Form&nbsp;10-K for the year ended June&nbsp;30, 2009 are an integral part of these financial statements.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c90623p9062301.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c90623p9062301.gif
M1TE&.#EAUP!6`'```"'Y!`$``/\`+`````#7`%8`A____^__]X2$A``I4HR<
MM1E"6FN$E.;W]P`I2B$06J6UQ;7.UA`Q2H2<G%ICG,[>UH1K6H1*6DI*6A#.
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ME&,9[Q`9[V/O6A#O6F.M6A"M6A`IE&/O&1#O&6.M&1"M&2D9$"E:$(S.6D+.
MWCK.6D*,WHR,6CJ,6D+.G$*,G#H(E(S.&3K.&8R,&3J,&;5SWF/.6A#.6F.,
M6A",6A`(E&/.&1#.&6.,&1",&0@9$`A:$$)C>Q!K6N:M:^9*[^9*:XR4YN:M
MK>9*K>9**>:M*;6M:[6M*;5[K>9[:[5*[[5*:^9[K;5*K;5**>9[*;5[:[5[
M*;6MC.:M2N9*SN9*2N:MC.9*C.9*".:M"+6M2K6M"+5[C.9[2K5*SK5*2N9[
MC+5*C+5*".9["+5[2K5["#I*E._FUC%C8[7FUE)C>RE:,0A:,>;F[UISA``0
M.B$Q4I2]Q8S%[VO%[VO%K6OO[XQKSCIKSHP0I6OOK8PISCHISF-KSA!KSF,0
MI6,ISA`ISFO%SFO%C&OOSHQ*SCI*SHP0A&OOC(P(SCH(SF-*SA!*SF,0A&,(
MSA`(SH1K*80I*5)K*5(I*1#O[Q"M[Q#OK1"MK1!KI81**80(*5)**5((*1#.
M[Q",[X1K"(0I"%)K"%(I"!#OSA"MSA#OC!"MC!!KA(1*"(0("%)*"%(("!#.
MSA",S@@I.M;O]RE"4@`04A`Q6CIKG(R$G/__[__>]P````C_``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$B1X+^*&#-JW,BQHT>)%S^*'$FRI$F-(4^J7,FR9<>4
M+F/*G$D3`,R:.'/J1+FSI\^?#&\"'4HTI]"B2).N/*JTJ=.73Z-*W<ATJM6K
M"*MBW8I5*]>O4;V"'9M4+-FS0,VB7:M3+=NW,]W"G<M2+MV[)>WBW>M1+]^_
M&?T"'@R2L.&\AQ-_%*RX<4'&CB-#CMQX,N7$EB\;SJQY,.?.?S^#WBMZ]-W2
MIN>B3OUV->NUKE^?7=UO8>V3MSOFQKB;9>^$OQN&##XPP,':M8T+O$U<H7'E
M!9LC9#XP]_.$T`TB+[XPN_2(O;,?_Z\>'<#WA"E_GR]XP.!U[PY[!U^_'GA%
M^/6YES\?7#S![]0=E=UU`HG7'GL`$*&+`;?,,LLM!BQ@BT$'Z@=`>[LI-R!Y
MR&E8$'P?FB?0@00"X.%V%X98X7OD8>?<B"VFZ-YR(EHHW47957A`<`=62%![
M1!@0BSX(X((``O;,<L]`/M)8VX0PRHC@CU%*N:.(M?4XXG;]6+=EC4Z":>*4
M4=YV98]9#C3ADV$RJ:*5;L*YG9;MI>2CCC%2B5Q[]QB@SP"`!HI`(1.*!^6,
M%-((8Y-D*NKH?W'"IR68!Q#QP`.,WJG=BRWZ:&9&S>%()993,IJ;!1<$*B@N
MA1"QZ'YZBO_9''7CM8BBC+T=2)P_N2DP"S^/QLBEF[J.*B:IX^%I[`'^4'F@
M66M.!P"O`O6)`*!_ZE-``0@H.=YNIK:G;)/C#M0LFY!6V*RI`$3;Y(3W$&#/
M+:,.V\^!T98G9;"3QGGLO@ZE5V.6TMUF2VY$%'(MH`480(`"!C0PH;C(MCME
M;]0V^F^53C8;+*0'%=LN`;D4`C"_(*<LH[@>'WLHF9^*>>7*PR$+KKGFM5SC
M`0M<P`##!MP3@"U$)ZN0QUW>VF1M+2/];X7(M:RESK6.R$^2<7KL#Z.X8A@E
MUQ?>1O6]`IUK+L;FB?R8F^=2[6^5M_5\)`(7+)#H<F[C;.QO>1?_Z[:F*O_8
M--PCDCR+?YK.5_:M]KF9VX$M1_UVV55J17;(58JK0"Z`(G"+$0VU9PNS4%-<
MD-,R-OMRUF"WJ'.:)Y=]X#T-8)WG0\2MF3>'D*(+7)?'_D/$\,-/N'KJ`Q$_
MO,<'*!#+M8,N,#31!S09@*46**#]`D0<?^'6`D'I*8(K#G3/UN>SG#FY!]AR
MC_LM0V>+X0%4GZ+I[+6?OJY,?_DCT41('\[L]YOV#.U]`@Q?02;T#P=`Z!8"
M>`!!_B80(A#@%@Z80X0&HH`_`>H"<R!`!@C0``7HZ``6R(`#"E&("[QB%@90
M`!'PA+WC^6Y$1%C`"WI4*>T)@0`/L\"2__*70UA<J(<$,(##""`A9\E+`D:P
MP`(L(,4F6FQ:1,@>$($H0_NE;5_5>\`6,I`!`V1``=QCT@,L(#XP$4$!2718
M!M@X013]8UOZT$<N%+`RO9GO%@@H``/P08`1*2!5'JQ`+BZ0BUS<PE45)$`+
M586`/UW``9@BB!$$4`@^8LAMM[&@!!H@K@<88!8MQ(<J+R`!`9@P2O.3`!\!
M`+%8Y$(?#,@%/F`HP0K-#Q_Z8*$P)3`+"U3H`4F<A006J<I"S((`,[R;!6=A
MRSPNLA#\L%NE&/0""BW``(7`1R/U@8]"1,ATS/G'`(YD#P;8K2$),Q("<E'(
M"RF@`-A:Y\*2-/_$(*4*>D=:YSH+,(L%'',6GANBK&"T``E@H)!!*D0N[+%(
M"10B%OA@``,N`$V"!,D>!#@``1BYRULT"!_VP(<!C+"B#.0BD(T$)CXD4`1#
MSD*<&V6A!&Q)40<8E$(6N`5*R^F@%C9R%@H(@!$8J0OR^$.2N92`2:DY4:0N
MS2:"8L`L]T6P:B%TG80LT"$'D$=]LK,02^K3!1:&K;*JJA`<8!+)<J%-1=U)
M7K%XP/5F80]S/DP6+UA`+?4(S0,%:0`/D^@M%/"`X3U``4*=%Q$"8!R1ZB,6
M6R3`$("820`T0)>S:``3I:@`%5Z@K^]DW@)NT<A;/,Q2CP4G`V*!QE?_[+%"
M]SCDH#+`O7N\<:2#,F%[D/:/LB)`JU7*6\+L,="DVA.?9-46,'/!@%M43[>!
MND`A3-I"M^(C`Y`$P`(*80]@X8U1#^"K!XQCP6PJE$D60&@GDV>``1C@`AQ]
MKXF"U$@"#%&D\_(/DU[@RLD:A`@9.*T!?)1>>\2"'T.$3@!66TX#O*(`6^49
M2HMY`,H6*``*(.\L)$B>XG8.'UMUG)1LH;"!UC,`J+J6MAP@QQCZ=A9$JF0L
M,J"+`,HB`X7PX`#J-CL#]#6:5/)8B/71U`H*+2$-U8<!(!FD/$H@:/ZYWBT8
MT*KP$8#+`C;?/80F'N/T:9$9]A,AER1@(O`#_[_;VBH16%N(GQHDMQ>0,OB6
MHTZR'C?%;4H1$?CJX@+I`I]'*L01W#>ZZA&`2&#MJ'+NH8M8!$K*%2(`/BZP
MU9NYN:_Z_8^/XL5E$A/!`=QR0*A)I`!Q-OD`M9N%RL#6&R-(E)0"L8`MIXP0
MY9SZ3P6P6_U(AF(05=#(=5835O/XYS:MBR#W:#$"PFK/?R+@%20VWRP$%30*
M$0"Z@PKOH.VQX-@E+!="*-_M!+(`6[ZR3PRP1Y,YMM];D%MT]%/4=PQDY$=>
M2%YU-M"'VEW)67[46]$YU3(S("5UXO*X*HA3<`8-/12+%=S))L@"A%PW`8]W
M8;FP@'(.P(]@AA=VS?^[K`4BM;$$2?25<QZ`!$@\OFKYJ=L`EC69PFR0#L["
M5>,N-T)PZR<,LQN8\XX1G^SM`.CT0YT,()(^`)V0`TA;'P2H;(S7F7$._@Q0
M:`V1B0RP,`3X=R#M9D`AU78`(QO@9="IGOL"^.0^23FM9.^V<Q[=Y7CEXG`*
M[!23*C7F&7:8EN6T&ZHX.BJNH6KJQN$[Z(S%I,U=()JU<3B1W/FJ:=VO@BT>
M`+4#<.C.%6+R-E^8/L#K6R+`(H"P%P(#H*?W"QD`%[RF$JJ*S9XLPG&)#U.`
M$8S@``;@^M0,8#A!H/2XS16BE_+2^>0J^-C2\F.$0;0@?NUF^7=BKCCCG3K_
M`.#M`#K1>W,6YW-T!X#<NT%[VX4VD2Y2M<Y72"]Y`I#Q`,S)CP8XS(P&(`09
M`$B0]G,$H0`,(`'&9!`DTW45!#&I)$Z-5`#X\$)#P@]\8@!J!S6C0GHEXRKS
MDR3*L1OB@TRWL$R+U$BZ%`L-LDC2<T\*Z'Z*DC`69RT.8`2.I3PY.#SS)W[J
MYV=&]S;%DC`+@P]-!F(8)PL$D5YMI2T%0$[ZD&=2*&3[]UX/8$M9%R7W,`L8
MD`$Z8D$253(/8E*W4`@[Q3FYX(4)`DC.)6H_XGS0%V!V)2+-<U.Y$`MC2(9V
M^%(!]V4.J!`'\`"O@`\BMX4($`LT!B$.X$",F$$&_^!`[%=(QO%TT=5L;4(K
MAAA_!S!_IK=R(G(/@$16G8,D1V(D9F56%Y!M%\(/`^!O&H=1KU0XIU4(!"!%
M.2A8210+#,`/\$)V]60Q,2,0FQ,+(/AEAS."BK(`.'8!#G,IQ%-]%^2"`*`+
M&V5GPY4S.7,;#Q!.306*4?>$>21(V[(MP#0`3ZA1:R<0#M=<CX(Z"8)0P/9B
M8\5UJO@`H9@MX$A.X'A+JD2!!!5>PKA]4F(`?Z=0S<-(M_``H38F5<8/[.6+
M^O*&)1.'TM<_QV8/'`603!(`E*9=*W=/G$9O!_%X=C-H7*9$_I<!_*!$+*F2
M9>0PWF<3>;1Y*18M3&,PH?]';0?9.?:W?&2'+84@@"(TE-A'E"4T,7^4"[GG
M<O0T0<@6DUGV9=WFC;^8*QST@>.7;R-Y6A*3.9HD`763($,B='>C.7G$1WU"
M;AO"*>K(?INW`+#S,13',/-V3Z:GA'(54*NG4![B86.".`T(22(U4^'%,Q*E
MANYW#T*0"\<'D5&B,^VA:<_W;[9#,;?A)R-6=>R&7RNWA?KP<X!3$$18@QZ`
M`+7'<\=A8K/'`$GG1]I62:)73SO)=9[H==F%>@T!/&@73LYU#P)P=TNH2IX(
M.QER<TL2)&KG=`BQ.3/W;V"&$/T&22-G$(OW3KJ@+2%%.0<1+_@4A+H@C:A9
M(%3_\@^5M)K"YB:5)2-S:8ZS-)N#0G.;N3`8!C:!B&0[8W,,4&X6(`'!]H:;
M=G_ZTAZV1D]`PH8Y0B,&Y'RN$B^V\RII66[I^1^UT8#OM%SV]RZ5%V3:,DL*
M(`$^J"&/`R<#09Y_$DA\5#_VTV$4(SJAAW7/,8_14Q#6HD^=)&%H1V,:61"M
M=GF;6$ZJ"`"[MX"4!Z1CB7=F)V`Z\YV3*5(,<#B9XB>WP#Q#!TAA66U-:F?L
MX2L%<`L5$)+C!TBM@C@P8QZ:=RT&H`M<!$1HFED&E8GL65EVR77>=R#SQU9(
M99!O5`B#-&7F!WI[]&O9*2(3YJ$9,)TT='OZ<'Q;]HM:_])\6)ES889L/WHG
MNA6#QS:+!/``>Y9#_&!+<Q1D[8E^6?@Q$\98CY$MJ!IU49='JXI+;\=BT%,`
MLEFG]1>3-L<MV,*,"J!%]V4/E42@4^)WG10+50IM9%<(0GIGFG9<&#A^&CBJ
M\G&5&8=^1G"@B+>+]\`U/#,+LQ<+,>EFI[5+,:0]!H""03->Z9<@1A8+QE0^
MXJ*,^%!3,-)GV6)6<W.O2!(T+,9<@22/:\5U>/DCVPAI[$=6>"0HTZ8`2&D0
M#>5"2MDOU_HY*7HAPW-?VI6?!6H/*=8DZZ*@["8!^1E-U<,L'$EV%]!CD(-%
M(59.=UB;U>(K$JA1]A"%M+@D/?]3I<8Q7GW512G"7@I@6Q;G#\6C>6XU>Y2D
M3]4E-'QU)%I56;J`#P&%K#$"8K/`+6474(+"C`8FA&0W2+%(*O&24<]DBPNP
M``1P4Q(@!'[2K-82J.X'AR/2`+D40V5K`4R4:QZJE+MZ*8(E)$HY4F$)+LB$
M2K'`0A#21##60B(GGH>44HME`8V5/4(R6P1@"QRY/>2)L/BZN:;I/H4P"`,P
ML[_806=EJ_!E`%;+5IW#96<G+;04;P88,J84KL[4(,M43@H`;P8@$/8(4AS"
M*`2``9/);K>@1Q>@3#/U3K:PLN3T(*@D3LR86ZIDNM0G6+L:0`2AI+9:AS'E
M("LD@4C_!27(Q`\$\`^%VT+#=+[")$R8-2$6BX?MJ8R%RXS9=BL!(`MG>P&(
M=BT%L%VY*R7`XR-S5K->\VSA`UD7(('7=$ZD%[XC@U0?<R7]\$U+*5[@!+T7
MD)`:\DW=Q4AB*$,`8(\>0&)QR1UE]F78EF0/(`2S@%_X0(':U0``FB!%4$+_
MH`"ZL*NZD,.[BL,XS,/:,UF!F#U2E&TYI#UHY#5<<P]]RR!*]#!/]A\ZHUK_
MNQ!(9$9!U".6(FX+\%[]8,!JTECOA41<9)_5TL0C)$/_U5B""1%;^%W,]R,'
M8`0$L)(.PUA>;"D+\`#_\!SO,9UC@C_B(G`1ZIH_PI&V8'CA_^DH`G8H[GI$
MAV<AFW(RRN(>*@J((^N75U4TY/(AK79;W3&RH4DZL:$0COP0;222N+(1F0(1
MK1,GKUP>\],`G=5KME9=D%3"L7P0I:PW,^/*51,[E5P1]+D[*G$/RX14T92>
M[VIO)[O+=Y,;MR$8C'(\PTP1N1$Y]7(<$+LLQV*1"[0<;">#]A$SAG4+>18+
M,60!PU,I.72VNI2=R@G-7Z..0^>5P5S"%&(P#U$N8:,0X!P17K-B'S-]Y*+/
M@?,C1L`/$M6\3ZQ$$H`/&"`!A24XC<(UNV$G#A&:]#8L"!''&#+0VCE!D+)G
M>^8CJ@,R7VP0QLR!(YT?ER,VC@*9]W-@`0R]:?B5T_BU6"_#L?:!T3?A/20M
M(BVS.N`R.$]#(6:C;^0<S-\CHLSB+[3"),QC)J\#C"--.5/SS\?B6P2P0D]8
M`*\P!^R,C/><)1E#-;_\#VS=UF[]UG`=UW(]UW1=UW9]UWB=UWJ]UWS=UWX-
%UP$!`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
